What's happening
This bill requires Medicaid to cover rapid whole genome sequencing for seriously ill children in intensive care to aid diagnosis and treatment.
Why it matters
Expands access to cutting-edge diagnostics for critically ill children. By requiring Medicaid to cover rapid whole genome sequencing for children in intensive or high-acuity hospital care with complex, unexplained illnesses, the bill could lead to faster and more accurate diagnoses, potentially improving outcomes for some of the sickest pediatric patients.
Establishes clear and specific clinical criteria for coverage. The bill outlines detailed eligibility requirements and medical necessity standards, ensuring that this expensive test is used judiciously—reserved for cases where timely genetic diagnosis is likely to significantly impact treatment decisions or where other testing would be less efficient or more invasive.
Imposes strict privacy and consent controls on genetic data. Genetic data produced under this program is tightly regulated as protected health information, and use in scientific research is only allowed with explicit patient or guardian consent, with the right to revoke permission and have data expunged—safeguarding sensitive personal information.
Allows for future updates and broader genetic testing coverage. The bill empowers the health commissioner to expand the list of qualifying conditions and to include other forms of advanced genetic testing as medical knowledge evolves, which could further improve care for children with rare or undiagnosed conditions.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Medicaid beneficiaries under 21 and their families
The bill would require payment for rapid whole genome sequencing for patients with qualifying unexplained complex or acute illnesses receiving intensive or other high-acuity hospital care, subject to any required federal approval.
Hospitals and treating clinicians
The bill would establish payment for qualifying testing and allow evidence-based medical necessity criteria tied to symptoms, suspected genetic conditions and the need to guide treatment.
New York’s Medicaid administrators
The commissioner would have to authorize payment one year after the section takes effect, issue payment rules and seek any federal approvals needed for federal financial participation.
Researchers using patient genetic data
Research use would require express patient or guardian consent, and written revocation would require researchers to stop using and expunge the data.
Headline styles
Fund Rapid Genome Testing
Plain English, a few words. Used as the page title.
Sponsors
1 Co-sponsor
History
- Committed to rules
- Advanced to third reading
- 2nd report cal.
- 1st report cal.996
- Reference changed to health
- Referred to social services
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Cover Fast Genome Testing
In Assembly Committee · Health · Sponsor Amy Paulin
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
7929
IN SENATE
January 3, 2024
Introduced by Sen. HOYLMAN-SIGAL -- read twice and ordered printed, and when printed to be committed to the Committee on Social Services
AN ACT to amend the social services law, in relation to payment for rapid whole genome sequencing
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The social services law is amended by adding a new section 367-y to read as follows:
§ 367-y. Payment for rapid whole genome sequencing. 1. For purposes of this section, "rapid whole genome sequencing" means an investigation of the entire human genome, including coding and non-coding regions and mitochondrial deoxyribonucleic acid, to identify disease-causing genetic changes that returns the preliminary positive results within seven days and final results within fifteen days from the date of receipt of the sample by the lab performing the test. "Rapid whole genome sequencing" includes patient-only whole genome sequencing and duo and trio whole genome sequencing of the patient and biological parent or parents.
2. One year after the effective date of this section, and subject to any required approval of the Centers for Medicare and Medicaid Services, the commissioner shall authorize the payment of medical assistance funds for rapid whole genome sequencing when the beneficiary:
(a) is under twenty-one years of age;
(b) has a complex or acute illness of unknown etiology, that is not confirmed to be caused by an environmental exposure, toxic ingestion, infection with normal response to therapy, or trauma; and
(c) is receiving hospital services in an intensive care unit or other high acuity care unit within a hospital.
3. Payment provided pursuant to this section may be subject to applicable evidence-based medical necessity criteria that shall be based on all of the following:
(a) the patient has symptoms that suggest a broad differential diagnosis that would require an evaluation by multiple genetic tests if rapid whole genome sequencing is not performed;
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD13237-02-4
(b) the patient's treating healthcare provider has determined that timely identification of a molecular diagnosis is necessary to guide clinical decision-making and testing results may guide the treatment or management of the patient's condition; and
(c) the patient has a complex or acute illness of unknown etiology including at least one of the following conditions:
(i) congenital anomalies involving at least two organ systems or complex/multiple congenital anomalies in one organ system;
(ii) specific organ malformations highly suggestive of a genetic etiology;
(iii) abnormal laboratory tests or abnormal chemistry profiles suggesting the presence of a genetic disease, complex metabolic disorder, or inborn error of metabolism;
(iv) refractory or severe hypoglycemia or hyperglycemia;
(v) abnormal response to therapy related to an underlying medical condition affecting vital organs or bodily systems;
(vi) severe muscle weakness, rigidity, or spasticity;
(vii) refractory seizures;
(viii) a high-risk stratification on evaluation for a brief resolved unexplained event with any of the following:
(A) a recurrent event without respiratory infection;
(B) a recurrent witnessed seizure-like event; or
(C) a recurrent cardiopulmonary resuscitation event;
(ix) abnormal cardiac diagnostic testing results suggestive of possible channelopathies, arrhythmias, cardiomyopathies, myocarditis, or structural heart disease;
(x) abnormal diagnostic imaging studies suggestive of underlying genetic condition;
(xi) abnormal physiologic function studies suggestive of an underlying genetic etiology; or
(xii) family genetic history related to the patient's condition.
4. The commissioner may add conditions to those contained in paragraph (c) of subdivision three of this section based upon new medical evidence and may provide coverage for rapid whole genome sequencing or other next generation sequencing and genetic testing in addition to the coverage required under this section.
5. (a) Except as provided in paragraph (b) of this subdivision, genetic data generated as a result of performing rapid whole genome sequencing covered pursuant to this section shall have a primary use of assisting the ordering health care professional and treating care team to diagnose and treat the patient, and as protected health information it shall be subject to the requirements applicable to protected health information as set forth in the Health Information Portability and Accountability Act ("HIPAA"), the Health Information Technology for Economic and Clinical Health Act, their attendant regulations, including but not limited to the HIPAA Privacy Rule as promulgated at 45 CFR Part 160 and Subparts A and E of 45 CFR Part 164, and any applicable state or local law.
(b) Genetic data generated from rapid whole genome sequencing, covered pursuant to this section, can be used in scientific research if consent for such use of the data has been expressly given by the patient, or the patient's legal guardian in the case of a minor. The patient, the patient's legal guardian in the case of a minor, or the patient's health care provider with the patient's consent, may request access to the results of the testing covered by this section for use in other clinical settings. A health care provider may only charge a fee to the patient based on the direct costs of producing the results in a format usable in other clinical settings. A patient, or patient's legal guardian in the case of a minor, shall have the right to rescind the original consent to the use of the data in scientific research at any time, and upon receipt of a written revocation of the consent the health care provider or other entity using the data shall cease use and expunge the data from any data repository where it is held.
6. The commissioner shall take any actions necessary to implement the provisions of this section, including, but not limited to:
(a) promulgating rules and regulations to provide for payment pursuant to this section;
(b) submitting to the Centers for Medicare and Medicaid Services any new waiver application, amendment to an existing waiver, or Medicaid state plan amendment necessary to ensure federal financial participation for Medicaid coverage pursuant to this section; and
(c) any other administrative action determined to be necessary to implement the requirements of this section.
§ 2. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the social services law, in relation to payment for rapid whole genome sequencing
Summary of provisions
Section one adds a new section 367-x to the social services law.
Subdivision one of section one defines "rapid whole genome sequencing." Subdivision two requires that one year after the effective date of the section and subject to approval by the Centers for Medicare and Medicaid Services, the Medicaid commissioner shall authorize the disbursement of Medicare and Medicaid funds to patients who are under 21 years of age, have an acute illness of unknown etiology and are receiving hospital services in an intensive care unit.
Subdivision three outlines evidence-based criteria on which payment provided pursuant to the new section may be based. Subdivision four authorizes the commissioner to add conditional criteria for Medicaid and Medicare payments based on new medical evidence.
Subdivision five outlines the primary that the primary use of genetic data generated as a result of rapid whole genome sequencing is to assist the medical team and treat the patient, that such data is subject to HIPAA protections, and that such data may be used for research purposes with the consent of the patient or their legal guardian.
Subdivision six authorizes the commissioner to promulgate rules and regulations necessary to implement the section.
Section 2 is the effective date.
Justification
Rapid whole genome sequencing (rWGS) is an innovative method of quickly diagnosing medical conditions stemming from genetic disorders in order to treat patients in medical crises. Unlike traditional genetic testing, rWGS analyzes a person's entire DNA sequence, rather than just a few genes. This makes it especially helpful in quickly diagnosing genetic medical conditions.
Genetic disorders are a leading contributor to death in neonatal and pediatric intensive care units in the United States. A University of California-San Francisco study found that when rWGS was used to treat infants suspected to have genetic diseases, 40% got a diagnosis within about a week reducing their hospital stay and resulting in changed medical care in one of three patients.
Despite rWGS's dramatic promise in neonatal critical care, few hospital- ized infants undergo rWGS, oftentimes because many private and public health insurers will not cover the expense, which can cost up to $8,000.
Some private health insurers, such as UnitedHealthcare and Cigna, already cover rWGS testing. But because four in ten children are covered by Medicaid in their first year of life in the United States, Medicaid coverage of rWGS would have a dramatic impact on access to rWGS and infant health. Eight state Medicaid programs have added or will soon add rWGS coverage since 2021.
A 2020 analysis of proposed rWGS Medicaid coverage in Florida found that savings to the state resulting from enhanced neonatal care enabled by rWGS would far outweigh the costs. Savings were estimated to exceed $3.7 million a nearly $2.9 million return on investment.
This bill would authorize the Medicaid commissioner to expand Medicaid coverage to rWGS testing when medically indicated, according to evidence-based criteria.
Prior legislative history
This is a new bill.
Fiscal implications
To be determined.
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.